Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the E2F1/Rb/HDAC1 axis with the small molecule HR488B effectively inhibits colorectal cancer growth

7 Dec 2023

Abstract excerpt

Colorectal cancer (CRC), the third most common cancer worldwide, remains highly lethal as the disease only becomes symptomatic at an advanced stage. Growing evidence suggests that histone deacetylases (HDACs), a group of epigenetic enzymes overexpressed in precancerous lesions of CRC, may represent promising molecular targets for CRC treatment. Histone deacetylase inhibitors (HDACis) have gradually become...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38062013
DOI: 10.1038/s41419-023-06205-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the E2F1/Rb/HDAC1 axis with the small molecule HR488B effectively inhibits colorectal cancer growthPMID 38062013Read ↗

Histone Deacetylases and their Inhibitors in Colorectal Cancer Therapy: Current Evidence and Future ConsiderationsSemantic proximity Read ↗

G9a/GLP inhibitor UNC0642 induces growth arrest in colorectal cancer via induction of ROS generation, coordinated overexpression of GADD genes, and the JNK/p38 MAPK pathwaySemantic proximity Read ↗

A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherinSemantic proximity Read ↗

Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancerSemantic proximity Read ↗

SIRT1: a novel regulator in colorectal cancerSemantic proximity Read ↗

Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal CancerSemantic proximity Read ↗

The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancySemantic proximity Read ↗

Ellagic acid: a potential inhibitor of enhancer of zeste homolog-2 and protein arginine methyltransferase-5Semantic proximity Read ↗

Targeting Histone Deacetylases: Opportunities for Cancer Treatment and ChemopreventionSemantic proximity Read ↗

Histone acetylation and chemoresistance in colorectal cancer : an opportunity for effective personalized treatmentSemantic proximity Read ↗

SelSA-1, a novel HDAC inhibitor demonstrates enhanced chemotherapeutic potential by redox modulationSemantic proximity Read ↗

Potential of histone deacetylase inhibitors for the therapy of ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.